CRSP has been the topic of several other reports. Canaccord Genuity lifted their target price on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the stock a positive rating in a research report on Wednesday, November 20th. Oppenheimer lifted their target price on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the stock an outperform rating in a research report on Monday, November 25th. Needham & Company LLC reiterated a buy rating and set a $84.00 target price on shares of Crispr Therapeutics in a research report on Monday, December 23rd. Piper Sandler reiterated a buy rating and set a $104.00 target price on shares of Crispr Therapeutics in a research report on Thursday, February 13th. Finally, Wells Fargo & Co restated a buy rating on shares of Crispr Therapeutics in a report on Friday, December 6th. One analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $73.04.
NASDAQ:CRSP opened at $38.96 on Thursday. The firm’s 50 day simple moving average is $50.16 and its 200 day simple moving average is $53.05. Crispr Therapeutics has a one year low of $32.30 and a one year high of $74.00. The company has a market cap of $2.37 billion, a PE ratio of 40.16 and a beta of 2.72.
Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Wednesday, February 12th. The company reported $0.51 EPS for the quarter, topping the consensus estimate of ($0.68) by $1.19. Crispr Therapeutics had a net margin of 23.09% and a return on equity of 11.74%. The business had revenue of $77.00 million for the quarter, compared to the consensus estimate of $39.08 million. During the same period last year, the company earned ($0.92) EPS. The firm’s revenue was up 76900.0% compared to the same quarter last year. On average, equities analysts predict that Crispr Therapeutics will post -4.54 earnings per share for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in CRSP. Orbimed Advisors LLC bought a new position in Crispr Therapeutics during the 3rd quarter worth approximately $21,167,000. FMR LLC increased its stake in shares of Crispr Therapeutics by 71.8% in the 4th quarter. FMR LLC now owns 952,369 shares of the company’s stock valued at $58,004,000 after acquiring an additional 398,012 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Crispr Therapeutics by 904.0% in the 4th quarter. Renaissance Technologies LLC now owns 394,564 shares of the company’s stock valued at $24,031,000 after acquiring an additional 355,264 shares in the last quarter. Nikko Asset Management Americas Inc. increased its stake in shares of Crispr Therapeutics by 9.8% in the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,049,553 shares of the company’s stock valued at $185,733,000 after acquiring an additional 272,139 shares in the last quarter. Finally, Capital International Investors increased its stake in shares of Crispr Therapeutics by 171.7% in the 4th quarter. Capital International Investors now owns 375,000 shares of the company’s stock valued at $22,839,000 after acquiring an additional 237,000 shares in the last quarter. Hedge funds and other institutional investors own 52.02% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: Why Invest in Dividend Achievers?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.